South Korea FDA Accused Of Lax Monitoring Of Sibutramine Drugs
This article was originally published in PharmAsia News
Executive Summary
South Korea's FDA is being criticized for being lax in its regulation of the weight-loss drug sibutramine, now banned in the United States, Europe and other markets